Navigation Links
Cochrane review on use of rectal artesunate for severe malaria
Date:5/30/2014

Researchers from the Cochrane Infectious Diseases Group, hosted at LSTM, conducted an independent review of the effects of pre-referral rectal artesunate for people with severe malaria, published in the Cochrane Library today. The review follows a large trial of rectal artesunate in 2009 which led the World Health Organization to recommend its use.

Severe malaria is a serious medical condition caused by infection with the Plasmodium parasite. It is treated by giving injections of antimalarial drugs, which need to be started as quickly as possible to reduce the risk of death and brain damage. In some rural areas where malaria is common, injections are unavailable and people often die before reaching hospital. In these areas rectal artesunate could feasibly be administered by volunteers without formal healthcare training, to start treatment before transporting the patient.

The Cochrane review authors searched extensively for other trials, but only the single trial from 2009 directly assessed pre-referral treatment. This trial enrolled over 17,000 patients at various sites across Ghana, Tanzania and Bangladesh, and trained village volunteers to recognize the symptoms of severe malaria, administer rectal artesunate, and refer all patients to hospital.

At the African sites, only children aged 6 to 72 months were enrolled and there were fewer deaths with rectal artesunate than with placebo. This expected finding was replicated in Asia, but complicated by the unexpected finding of more deaths with artesunate in older children (aged >72 months) and adults. The trial was well designed to minimize bias, but the number of deaths in the older age group was very low. Consequently, there is the possibility that this finding occurred by chance but without further trials neither the trial authors, nor the review authors were able to reliably explain this finding.

Joseph Okebe, the lead author of the review said: "In rural areas without access to injectable antimalarials rectal artesunate probably reduces deaths in young children. However, the low quality evidence that it is harmful in older children and adults must be taken into account when formulating national policies on pre-referral treatment."


'/>"/>

Contact: Clare Bebb
c.bebb@liv.ac.uk
44-015-170-53135
Liverpool School of Tropical Medicine
Source:Eurekalert

Related medicine news :

1. Wound care meta-review draws firm conclusions from Cochrane published studies
2. Cochrane finds no reliable evidence on effectiveness of electric fans in heatwaves
3. Omega-3 Supplements No Help Against Repeat Heart Trouble: Review
4. AADR comments on review that validates association between oral health and heart health
5. IUDs Work as Emergency Contraceptive: Review
6. ICU stays for worst asthma drop 74 percent, review finds
7. Antiretroviral treatment for preventing HIV infection: an evidence review for physicians
8. TheBestHeartRateMonitorReviews.com Announces The Top 3 Heart Rate Monitors
9. US Drug Watchdog Now Offers To Get A Free Legal Review For All DePuy ASR Recipients Who Received A Letter From Broadspire About Their Recalled DePuy Hip Implant
10. University of Nevada School of Medicine researcher reviews muscular dystrophy therapies
11. Metabolic Cooking Review For Karine Losier and Dave Ruel's Diet And Cookbook Program Released
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology: